, de l'incidence et de la mortalité par cancer en France entre 1980 et 2012: étude à partir des registres des cancers du réseau Francim, 2013.
, Survie des personnes atteintes de cancer en France métropolitaine 1989-2013 -Partie 2 : hémopathies malignes / 2016 / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil [Internet
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and, Blood. 16 avr, vol.113, issue.16, pp.3666-72, 2005. ,
Prognostic factors for acute myeloid leukaemia in adults -biological significance and clinical use, Br J Haematol. avr, vol.165, issue.1, pp.17-38, 2014. ,
Age and acute myeloid leukemia, Blood. 1 mai, vol.107, issue.9, pp.3481-3486, 2006. ,
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups, Haematologica. sept, vol.89, issue.9, pp.1082-90, 2004. ,
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes, Lancet Lond Engl. 11 déc, vol.376, issue.9757, pp.2000-2008, 2010. ,
The outcomes and costs of acute myeloid leukemia among the elderly, Arch Intern Med. 22 juill, vol.162, issue.14, pp.1597-603, 2002. ,
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia, Br J Haematol. févr, vol.136, issue.4, pp.624-631, 2007. ,
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome, Haematologica. févr, vol.98, issue.2, pp.208-224, 2013. ,
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, vol.15, issue.8, pp.2912-2921, 2005. ,
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 30 avr, vol.113, pp.4179-87, 2009. ,
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.31, pp.3641-3650, 2015. ,
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry, Am J Hematol. mars, vol.90, issue.3, pp.208-222, 2015. ,
The impact of therapyrelated acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, Blood. 17 févr, vol.117, issue.7, pp.2137-2182, 2011. ,
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo corebinding factor leukemia, Cancer. 15 juill, vol.115, issue.14, pp.3217-3238, 2009. ,
The leukemia strikes back: a review of pathogenesis and treatment of secondary AML, Ann Hematol. mars, vol.98, issue.3, pp.541-59, 2019. ,
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG), Trial. Blood. 1 janv, vol.101, issue.1, pp.64-70, 1992. ,
Minimal Residual Disease in Acute Myeloid Leukemia, Curr Treat Options Oncol, vol.18, issue.1, p.1, 2017. ,
The emerging role of measurable residual disease detection in AML in morphologic remission, Semin Hematol. avr, vol.56, issue.2, pp.125-155, 2019. ,
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group, Br J Haematol. août, vol.33, issue.4, pp.451-459, 1976. ,
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-AmericanBritish Cooperative Group, Ann Intern Med, vol.103, issue.4, pp.620-625, 1985. ,
The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues, Ann Oncol. déc, vol.10, issue.12, pp.1419-1451, 1999. ,
The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, issue.7, pp.2292-302, 2002. ,
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood. 30 juill, vol.114, issue.5, pp.937-51, 2009. ,
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood. 19 mai, vol.127, issue.20, pp.2391-405, 2016. ,
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Blood. 22 juill, vol.116, issue.3, pp.354-65, 2010. ,
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study, Blood. 15 déc, vol.96, issue.13, pp.4075-83, 2000. ,
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461), Blood. 15 déc, vol.100, issue.13, pp.4325-4361, 2002. ,
Cytogenetics in acute leukemia, Blood Rev. juin, vol.18, issue.2, pp.115-151, 2004. ,
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood. 21 janv, vol.115, issue.3, pp.453-74, 2010. ,
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.26, issue.4, pp.424-471, 2017. ,
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia, N Engl J Med. 1 mai, vol.358, issue.18, pp.1909-1927, 2008. ,
An update of current treatments for adult acute myeloid leukemia, Blood. 7 janv, vol.127, issue.1, pp.53-61, 2016. ,
Acute Myeloid Leukemia. Longo DL, éditeur, N Engl J Med. 17 sept, vol.373, issue.12, pp.1136-52, 2015. ,
Anthracycline dose intensification in acute myeloid leukemia, N Engl J Med. 24 sept, vol.361, issue.13, pp.1249-59, 2009. ,
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N Engl J Med. 22 mars, vol.366, issue.12, pp.1079-89, 2012. ,
RANDOMIZED COMPARISON OF 90 MG VERSUS 60 MG DAUNORUBICIN IN 7+3 ,
,
4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia, Cancer Res. 15 janv, vol.49, issue.2, pp.477-81, 1989. ,
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells, Blood. 15 juin, vol.79, issue.12, pp.3267-73, 1992. ,
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.32, pp.5397-403, 2009. ,
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study, Blood. 22 mars, vol.119, issue.12, pp.2943-2951, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00849702
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older, J Clin Oncol Off J Am Soc Clin Oncol. 20 janv, vol.31, issue.3, pp.321-328, 2013. ,
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia, Leukemia. févr, vol.28, issue.2, pp.440-443, 2014. ,
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia, Clin Drug Investig. févr, vol.37, issue.2, pp.167-74, 2017. ,
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, Lancet Lond Engl. 21 avr, vol.379, issue.9825, pp.1508-1524, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01056520
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.29, issue.4, pp.369-77, 2011. ,
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML, J Clin Oncol. 20 mai, vol.34, pp.7000-7000, 2016. ,
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation, N Engl J Med. 3 août, vol.377, issue.5, pp.454-64, 2017. ,
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B, N Engl J Med, vol.331, issue.14, pp.896-903, 1994. ,
Cytarabine dose for acute myeloid leukemia, N Engl J Med. 17 mars, vol.364, issue.11, pp.1027-1063, 2011. ,
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.28, issue.4, pp.586-95, 2010. ,
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial, J Clin Oncol Off J Am Soc Clin Oncol. 20 sept, vol.31, issue.27, pp.3360-3368, 2013. ,
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study, Blood. 24 févr, vol.117, issue.8, pp.2366-72, 2011. ,
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study, Blood. 18 août, vol.118, issue.7, pp.1754-62, 2011. ,
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and metaanalysis of prospective clinical trials, JAMA. 10 juin, vol.301, issue.22, pp.2349-61, 2009. ,
,
, Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories, J Clin Oncol Off J Am Soc Clin Oncol. 10 juin, vol.30, issue.17, pp.2140-2146, 2012.
,
, Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT, Haematologica. févr, vol.101, issue.2, pp.248-55, 2016.
Acute myeloid leukemia in the elderly: therapeutic options and choice, Leuk Lymphoma, vol.59, issue.2, pp.274-87, 2018. ,
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study, Lancet Oncol. sept, vol.16, issue.9, pp.1025-1061, 2015. ,
Final safety and efficacy data from the phase III QuANTUM-R study -oral abstract from ASH, 2018. ,
,
The molecular basis of leukemia, Hematol Am Soc Hematol Educ Program, pp.80-97, 2004. ,
, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med. 30 mai, vol.368, issue.22, pp.2059-74, 2013.
The roles of FLT3 in hematopoiesis and leukemia, Blood. 1 sept, vol.100, issue.5, pp.1532-1574, 2002. ,
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia, Leukemia. déc, vol.10, issue.12, pp.1911-1919, 1996. ,
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis, Blood. 15 juin, vol.99, issue.12, pp.4326-4361, 2002. ,
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials, Blood. 15 sept, vol.98, issue.6, pp.1752-1761, 2001. ,
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies, Blood. 15 avr, vol.97, issue.8, pp.2434-2443, 2001. ,
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a metaanalysis, Leukemia. août, vol.19, issue.8, pp.1345-1354, 2005. ,
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia, Blood. 1 mars, vol.111, issue.5, pp.2776-84, 2008. ,
Impact of FLT3-ITD length on prognosis of acute myeloid leukemia, Haematologica. 3 août, 2018. ,
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome, Blood. 17 sept, vol.114, issue.12, pp.2386-92, 2009. ,
FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype, Leuk Res. juin, vol.28, issue.6, pp.547-50, 2004. ,
Cooperating gene mutations in acute myeloid leukemia: a review of the literature, Leukemia. mai, vol.22, issue.5, pp.915-946, 2008. ,
RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis, Clin Chim Acta. févr, vol.489, pp.254-60, 2019. ,
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood. 21 mars, vol.121, issue.12, pp.2213-2236, 2013. ,
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature. 9 déc, vol.468, issue.7325, pp.839-882, 2010. ,
, Mutation in TET2 in myeloid cancers
,
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics, Blood, vol.118, issue.14, pp.3803-3813, 2011. ,
TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia, J Cell Physiol. août, vol.233, issue.8, pp.5838-5884, 2018. ,
, TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. -PubMed -NCBI
,
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes, Oncotarget, vol.8, issue.63, pp.106948-61, 2017. ,
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia, Nat Genet. 13 mars, vol.43, issue.4, pp.309-324, 2011. ,
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.29, issue.21, pp.2889-96, 2011. ,
, Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
,
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms, Leukemia. nov, vol.29, issue.11, pp.2134-2176, 2015. ,
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives, J Blood Med, vol.7, p.171, 2016. ,
Targeting the IDH2 Pathway in Acute Myeloid Leukemia, Clin Cancer Res. 16 mai, 2018. ,
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation, Blood. 14 juill, vol.118, issue.2, pp.409-421, 2011. ,
Serum 2-hydroxyglutarate production in IDH1-and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.32, issue.4, pp.297-305, 2014. ,
Molecular genetics of human leukemias: new insights into therapy. Semin Hematol, vol.39, pp.6-11, 2002. ,
Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias, Blood. 15 mars, vol.93, issue.6, pp.1817-1841, 1999. ,
EBPalpha mutations in acute myeloid leukaemias, Nat Rev Cancer. mai, vol.4, issue.5, pp.394-400, 2004. ,
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.28, issue.4, pp.570-577, 2010. ,
, Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that, PubMed -NCBI
Population-based agespecific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica, vol.90, pp.1502-1512, 2005. ,
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br J Haematol. juin, vol.145, issue.6, pp.788-800, 2009. ,
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression, Cancer Cell. 14 août, vol.22, issue.2, pp.180-93, 2012. ,
Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations, J Clin Invest, vol.123, issue.11, pp.4627-4667, 2013. ,
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features, Blood. 1 févr, vol.109, issue.3, pp.874-85, 2007. ,
, Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
,
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations, Blood. 1 déc, vol.106, issue.12, pp.3740-3746, 2005. ,
, Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expres, PubMed -NCBI
, Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
,
, Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution
Minimal Residual Disease in NPM1-Mutated AML, N Engl J Med. 4 févr, vol.374, issue.5, pp.481-483, 2016. ,
The p53 tumour suppressor gene, Nature. 6 juin, vol.351, issue.6326, pp.453-459, 1991. ,
TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis, Leukemia. janv, vol.23, issue.1, pp.203-209, 2009. ,
, TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal, PubMed -NCBI
Functional precision cancer medicine-moving beyond pure genomics, Nat Med. 8 sept, vol.23, issue.9, pp.1028-1063, 2017. ,
Complete molecular remission in chronic myelogenous leukemia after imatinib therapy, N Engl J Med. 15 août, vol.347, issue.7, pp.539-579, 2002. ,
Trastuzumab treatment in breast cancer, N Engl J Med. 18 mai, vol.354, p.2186, 1920. ,
Targeted therapy for HER2 positive breast cancer, J Hematol OncolJ Hematol Oncol. 3 juin, vol.6, p.38, 2013. ,
Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med. 1 janv, vol.372, issue.1, pp.30-39, 2015. ,
Crizotinib: a new treatment option for ALKpositive non-small cell lung cancer, Ann Pharmacother. févr, vol.47, issue.2, pp.189-97, 2013. ,
Equal access to innovative therapies and precision cancer care, Nat Rev Clin Oncol. 22 mars, vol.13, p.385, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01792383
Novel Precision Medicine Trial Designs: Umbrellas and Baskets, JAMA Oncol. 1 mars, vol.3, issue.3, p.423, 2017. ,
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.33, pp.4877-83, 2010. ,
Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses, Clin Cancer Res. 15 sept, vol.20, issue.18, pp.4827-4863, 2014. ,
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers ,
, Trial. Cancer Discov, vol.7, issue.6, pp.586-95, 2017.
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials, J Clin Oncol, vol.33, issue.32, pp.3817-3842, 2015. ,
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval, J Natl Cancer Inst, vol.107, issue.11, 2015. ,
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol, vol.16, issue.13, pp.1324-1358, 2015. ,
Precision medicine: lessons learned from the SHIVA trial, Lancet Oncol. déc, vol.16, issue.16, pp.579-80, 2015. ,
Precision medicine in acute myeloid leukemia: Hope, hype or both?, Leuk Res, vol.48, pp.73-80, 2016. ,
, Thérapies ciblées : modes d'action -Thérapies ciblées et immunothérapie spécifique
,
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood. août, vol.72, issue.2, pp.567-72, 1988. ,
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia, Blood. 15 mai, vol.85, issue.10, pp.2643-53, 1995. ,
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise, Int J Mol Sci. 23 avr, vol.20, issue.8, 2019. ,
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML), Blood, vol.114, issue.14, pp.2984-92, 2009. ,
FLT3 inhibitors in acute myeloid leukemia, J Hematol OncolJ Hematol Oncol, vol.4, issue.2018 ,
Treatment with FLT3 inhibitor in patients with FLT3 -mutated acute myeloid leukemia is associated with development of secondary FLT3 -tyrosine kinase domain mutations: FLT3 Inhibitor Treatment in Mutated AML, Cancer. 15 juill, vol.120, issue.14, pp.2142-2151, 2014. ,
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia, Clin Cancer Res, vol.19, issue.20, pp.5758-68, 2013. ,
Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer, vol.184, pp.61-70, 2010. ,
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood. 1 mai, vol.101, issue.9, pp.3597-605, 2003. ,
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia, J Natl Cancer Inst. 6 févr, vol.100, issue.3, 2008. ,
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada, Clinical Trials Group Study. Leuk Lymphoma. févr, vol.51, issue.2, pp.252-60, 2010. ,
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 10 avr, vol.28, issue.11, pp.1856-62, 2010. ,
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3 -mutated acute myeloid leukemia: CALGB 11001, Blood Adv. 24 janv, vol.1, issue.5, pp.331-371, 2017. ,
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial, Lancet Oncol. déc, vol.16, issue.16, pp.1691-1700, 2015. ,
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation, Ann Hematol, vol.94, issue.11, pp.1899-905, 2015. ,
Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation, Cancer. 1 mai, vol.124, issue.9, pp.1954-63, 2018. ,
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3 -ITD acute myeloid leukaemia in first complete remission, Br J Haematol, vol.175, issue.3, pp.496-504, 2016. ,
SORMAIN study of maintenance therapy with sorafenib in patients with FLT3-ITD acute myeloid leukemia -oral abstract from ASH, 2018. ,
,
Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation ,
, Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi. avr, vol.37, issue.4, pp.292-298, 2016.
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation, Eur J Cancer, vol.86, pp.233-242, 2017. ,
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia, Clin Lymphoma Myeloma Leuk. juin, vol.15, pp.73-82, 2015. ,
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation, Blood. 6 juin, vol.121, issue.23, pp.4655-62, 2013. ,
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients, Clin Lymphoma Myeloma Leuk. juill, vol.15, issue.7, pp.428-432, 2015. ,
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome, Am J Hematol. avr, vol.90, issue.4, pp.276-81, 2015. ,
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia, Pharmacotherapy. déc, vol.33, issue.12, pp.1341-52, 2013. ,
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res Off J Am Assoc Cancer Res. janv, vol.9, issue.1, pp.327-364, 2003. ,
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease, Blood. 28 sept, vol.105, issue.3, pp.986-93, 2004. ,
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations, Br J Haematol. juin, vol.169, issue.5, pp.694-700, 2015. ,
,
AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms, Mol Cancer, vol.12, issue.1, p.19, 2013. ,
Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant, J Clin Oncol. 20 mai, vol.31, pp.7012-7012, 2013. ,
Efficacy and safety of quizartinib (AC220) in patients age ? 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML), J Clin Oncol. 20 mai, vol.31, pp.7023-7023, 2013. ,
, Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia, | Journal of Clinical Oncology
, 160. Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | Blood Journal
,
, The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML, | Journal of Clinical Oncology
,
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia, Am J Hematol. févr, vol.93, issue.2, pp.213-234, 2018. ,
, The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial | Blood Journal
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia, Oncotarget, vol.8, issue.10, 2017. ,
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia, Blood, vol.21, issue.22, pp.3607-3622, 2013. ,
, Low Relapse Rate in Younger Patients ? 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy | Blood Journal
Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML) | Blood Journal ,
,
, Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML | Blood Journal
,
Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML, Blood. 2 déc, vol.128, issue.22, pp.2744-2744, 2016. ,
Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations, Blood. 6 déc, vol.124, issue.21, pp.389-389, 2014. ,
CAR T-cells targeting FLT3 have potent activity against FLT3?ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib, Leukemia. mai, vol.32, issue.5, pp.1168-79, 2018. ,
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia, Invest New Drugs, vol.35, issue.5, pp.556-65, 2017. ,
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor, Blood, vol.12, issue.2, pp.257-60, 2017. ,
Combination of gilteritinib with induction and consolidation chemotherapy for the treatment of patients with newly diagnosed acute myeloid leukemia ,
,
, First Global Approval. Drugs. févr, vol.79, issue.3, pp.331-340, 2019.
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia, Curr Hematol Malig Rep. déc, vol.12, issue.6, pp.537-583, 2017. ,
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML, N Engl J Med. 21 juin, vol.378, issue.25, pp.2386-98, 2018. ,
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation, Science. 3 mai, vol.340, issue.6132, pp.622-628, 2013. ,
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations, Cancer Discov. mai, vol.7, issue.5, pp.478-93, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01568357
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response, Blood, vol.10, issue.6, pp.732-773, 2017. ,
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia, Blood, vol.10, issue.6, pp.722-753, 2017. ,
Ivosidenib or enasidenib in combination with induction and consolidation therapy in newly diagnosed acute myeloid leukemia with IDH or IDH2 mutation -oral abstract presented at ASH, 2018. ,
Enasidenib in previously untreated IDH2-mutated acute myeloid leukemia -results from the Beat AML Master Trial -oral abstract from ASH, 2018. ,
idh2-mutated-acute-myeloid-leukemia-results-from-the-beat-aml-master-trial?_&___prerender 184. Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models | Blood Journal ,
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations, Nature, vol.559, issue.7712, pp.125-134, 2018. ,
The hallmarks of cancer, Cell. 7 janv, vol.100, issue.1, pp.57-70, 2000. ,
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome, Front Oncol, vol.9, p.192, 2019. ,
Deregulation of apoptosis in acute myeloid leukemia, Haematologica. janv, vol.92, issue.1, pp.81-94, 2007. ,
Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival, Proc Natl Acad Sci, vol.96, issue.26, pp.14943-14951, 1999. ,
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia, Blood. 3 janv, vol.133, issue.1, pp.7-17, 2019. ,
, Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes | Blood Journal
Venetoclax in combination with chemotherapy in elderly patients with acute myeloid leukemia -CAVEAT study -Oral abstract from ASH, 2018. ,
,
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia, Haematologica. sept, vol.103, issue.9, pp.404-411, 2018. ,
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies, Am J Hematol. mars, vol.93, issue.3, pp.401-408, 2018. ,
BCL-2 inhibition in AML: an unexpected bonus? Blood. 6 sept, vol.132, pp.1007-1019, 2018. ,
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia, Cancer Discov, vol.6, issue.10, pp.1106-1123, 2016. ,
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1, Leukemia. févr, vol.32, issue.2, pp.303-315, 2018. ,
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia, Leukemia. avr, vol.33, issue.4, pp.905-922, 2019. ,
Pharmacological activation of wild-type p53 in the therapy of leukemia, Exp Hematol. sept, vol.44, issue.9, pp.791-799, 2016. ,
, PHASE 1B/2 COMBINATION STUDY OF APR-246 AND AZACITIDINE (AZA) IN... by David Sallman
,
Targeting apoptosis in acute myeloid leukaemia, Br J Cancer, vol.117, issue.8, pp.1089-98, 2017. ,
Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of, Acute Myeloid Leukemia. Front Oncol, vol.8, p.41, 2018. ,
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes, Expert Opin Investig Drugs, vol.25, issue.3, pp.307-324, 2016. ,
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?, Ther Adv Hematol, vol.10, p.2040620718816698, 2019. ,
New Treatment Options for Acute Myeloid Leukemia in 2019, Curr Oncol Rep. 4 févr, vol.21, issue.2, p.16, 2019. ,
Nucleosidic DNA demethylating epigenetic drugs -A comprehensive review from discovery to clinic, Pharmacol Ther, vol.188, pp.45-79, 2018. ,
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.28, issue.4, pp.562-571, 2010. ,
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol. mars, vol.10, issue.3, pp.223-255, 2009. ,
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood. 16 juill, vol.126, issue.3, pp.291-300, 2015. ,
,
, Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group, Ann Hematol, vol.93, issue.11, pp.1825-1863, 2014.
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients, Am J Hematol. avr, vol.89, issue.4, pp.410-416, 2014. ,
Azacitidine for the treatment of relapsed and refractory AML in older patients, Leuk Res. févr, vol.39, issue.2, pp.124-154, 2015. ,
, Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients, J Hematol OncolJ Hematol Oncol. 16 avr, vol.6, p.29, 2013. ,
Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy, Asia Pac J Clin Oncol. mars, vol.11, issue.1, pp.54-61, 2015. ,
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms, Leukemia. janv, vol.28, issue.1, pp.78-87, 2014. ,
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes, Leukemia. avr, vol.30, issue.4, pp.889-96, 2016. ,
,
phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.30, issue.21, pp.2670-2677, 2012. ,
10-day vs 5-day decitabine: equivalence cannot be concluded, Lancet Haematol, vol.6, issue.4, p.177, 2019. ,
,
, in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial, Lancet Oncol, vol.18, issue.10, pp.1317-1343, 2017.
, Phase III ASTRAL-1 Study of Guadecitabine in Patients With Treatment-Naive AML Ineligible to Receive Intensive Induction Chemotherapy -The ASCO Post
,
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions, Biochim Biophys Acta. déc, vol.1799, pp.717-742, 2010. ,
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia, Blood. 1 févr, vol.105, issue.3, pp.959-67, 2005. ,
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes, Clin Cancer Res Off J Am Assoc Cancer Res. 1 févr, vol.14, issue.3, pp.826-858, 2008. ,
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia, Clin Cancer Res Off J Am Assoc Cancer Res. 1 avr, vol.19, issue.7, pp.1838-51, 2013. ,
Phase Ia/II, twoarm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies, Leukemia. août, vol.27, issue.8, pp.1628-1664, 2013. ,
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia, Nature. 3 août, vol.478, issue.7370, pp.524-532, 2011. ,
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy, Future Sci OA. mars, vol.5, issue.3, p.372, 2019. ,
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML), Expert Opin Investig Drugs. 3 juill, vol.26, issue.7, pp.803-814, 2017. ,
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study, Lancet Haematol. avr, vol.3, issue.4, pp.186-195, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01791279
, a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data, -human study of ABBV-075 (mivebresib)
,
Predicting response to BET inhibitors using computational modeling: A BEAT AML project study, Leuk Res. févr, vol.77, pp.42-50, 2019. ,
hDOT1L links histone methylation to leukemogenesis, Cell. 22 avr, vol.121, issue.2, pp.167-78, 2005. ,
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition, Haematologica. mai, vol.100, issue.5, pp.190-193, 2015. ,
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia, Blood. 14 juin, vol.131, issue.24, pp.2661-2670, 2018. ,
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia, Blood, vol.18, issue.7, pp.971-81, 2016. ,
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia, Cancer Discov, vol.6, issue.10, pp.1166-81, 2016. ,
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells, J Pharmacol Exp Ther. sept, vol.350, issue.3, pp.646-56, 2014. ,
Histone demethylase LSD1 regulates hematopoietic stem cells homeostasis and protects from death by endotoxic shock, Proc Natl Acad Sci, vol.9, issue.2, pp.244-52, 2018. ,
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells, Leukemia. nov, vol.28, issue.11, pp.2155-64, 2014. ,
Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy, OncoTargets Ther. 28 déc, vol.11, pp.131-55, 2017. ,
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905, J Clin Oncol Off J Am Soc Clin Oncol. 20 avr, vol.32, issue.12, pp.1242-1250, 2014. ,
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117, J Clin Oncol Off J Am Soc Clin Oncol. 20 août, vol.35, issue.24, pp.2745-53, 2017. ,
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study, Blood Adv. 26 févr, vol.3, issue.4, pp.508-526, 2019. ,
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes, Cancer. 15 mai, vol.123, issue.6, pp.994-1002, 2017. ,
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia, Cancer. 15 févr, vol.121, issue.4, pp.556-61, 2015. ,
Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in, Myeloid Leukemic Cells. Front Oncol, vol.7, p.19, 2017. ,
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells, Blood. 24 sept, vol.114, issue.13, pp.2733-2776, 2009. ,
Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia, Cancer Chemother Pharmacol, vol.24, issue.4, pp.203-213, 1989. ,
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms, Leuk Lymphoma, vol.57, issue.6, pp.1311-1319, 2016. ,
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML, Blood. 11 août, vol.118, issue.6, pp.1472-80, 2011. ,
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia, Leukemia. mars, vol.30, issue.3, pp.555-61, 2016. ,
Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia ,
, Zhongguo Shi Yan Xue Ye Xue Za Zhi. avr, vol.27, issue.2, pp.494-503, 2019.
LBH-589 (panobinostat) potentiates fludarabine antileukemic activity through a JNK-and XIAP-dependent mechanism, Leuk Res. avr, vol.36, issue.4, pp.491-499, 2012. ,
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome, J Clin Oncol Off J Am Soc Clin Oncol. 20 juin, vol.30, issue.18, pp.2204-2214, 2012. ,
, SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat
, Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) | Blood Journal
,
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study, Haematologica. oct, vol.100, issue.10, pp.1294-300, 2015. ,
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells, Leuk Res. juill, vol.34, issue.7, pp.899-905, 2010. ,
,
, Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment, Int J Mol Sci. 31 juill, vol.18, issue.8, 2017.
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes, Leukemia, vol.32, issue.5, pp.1094-105, 2018. ,
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation, Oncotarget. 20 avr, vol.6, issue.11, pp.9612-9638, 2015. ,
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses, Cell. 27 août, vol.162, issue.5, pp.974-86, 2015. ,
, BMS-936558) in Combination With 5-Azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML, An Open-Label Phase II Study of Nivolumab
, Years) Patients -AdisInsight
Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment, Cells. 3 avr, vol.8, issue.4, 2019. ,
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial, Br J Haematol. mai, vol.185, issue.3, pp.595-603, 2019. ,
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome, Leukemia. févr, vol.33, issue.2, pp.379-89, 2019. ,
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results, Am J Hematol, vol.93, issue.11, pp.1301-1311, 2018. ,
, Paper: Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies
Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia, Oncotarget. 25 avr, vol.8, issue.17, pp.29187-201, 2017. ,
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or highrisk myeloid leukemia, Leukemia, vol.25, issue.10, pp.1543-1550, 2011. ,
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia, Blood. 15 févr, vol.109, issue.4, pp.1387-94, 2007. ,
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia, Blood. 15 juin, vol.109, issue.12, pp.5151-5157, 2007. ,
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432, Leuk Res. mars, vol.38, issue.3, pp.329-362, 2014. ,
Targeting RAS signalling pathways in cancer therapy, Nat Rev Cancer. janv, vol.3, issue.1, pp.11-22, 2003. ,
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells, Int J Cancer. 20 mai, vol.115, issue.1, pp.65-73, 2005. ,
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia, Oncotarget. 13 sept, vol.7, issue.37, pp.59273-86, 2016. ,
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras, Nature. 17 sept, vol.461, issue.7262, pp.411-415, 2009. ,
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial, Clin Cancer Res Off J Am Assoc Cancer Res. 15 janv, vol.20, issue.2, pp.490-498, 2014. ,
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies, Cancer, vol.15, issue.12, pp.1871-1880, 2016. ,
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia, Clin Lymphoma Myeloma Leuk. mars, vol.19, issue.3, pp.142-148, 2019. ,
Survival of acute myeloid leukemia cells requires PI3 kinase activation, Blood. 1 août, vol.102, issue.3, pp.972-80, 2003. ,
Targeting PI3K/AKT/mTOR network for treatment of leukemia, Cell Mol Life Sci CMLS. juin, vol.72, issue.12, pp.2337-2384, 2015. ,
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias, Am J Hematol. janv, vol.92, issue.1, pp.7-11, 2017. ,
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia, Clin Cancer Res Off J Am Assoc Cancer Res, vol.15, issue.21, pp.6732-6741, 2009. ,
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107), Br J Haematol. janv, vol.156, issue.2, pp.205-217, 2012. ,
Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence, Ther Adv Hematol. févr, vol.7, issue.1, pp.40-51, 2016. ,
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia, Blood. 26 avr, vol.119, issue.17, pp.3917-3941, 2012. ,
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia, Haematologica, vol.103, issue.8, pp.1308-1324, 2018. ,
Adhesion Deregulation in Acute Myeloid Leukaemia, Cells. 17 janv, vol.8, issue.1, 2019. ,
Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside, Korean J Intern Med. mars, vol.32, issue.2, pp.248-57, 2017. ,
Limits to Personalized Cancer Medicine, N Engl J Med. 29 sept, vol.375, issue.13, pp.1289-94, 2016. ,
Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae : can we apply "precision medicine" to antimicrobial chemotherapy?, Expert Opin Pharmacother. 12 avr, vol.17, issue.6, pp.761-81, 2016. ,
Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells, Cancer Res, vol.44, issue.10, pp.4648-52, 1984. ,
Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia, Br J Cancer. août, vol.60, issue.2, pp.206-216, 1989. ,
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia, Br J Haematol. juin, vol.93, issue.4, pp.903-913, 1996. ,
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study, Lancet Haematol. déc, vol.4, issue.12, pp.595-606, 2017. ,
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study, Leuk Res. janv, vol.64, pp.34-41, 2018. ,
Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors, Blood, vol.16, issue.24, pp.3054-61, 2016. ,
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia, Cancer Discov. 1 déc, vol.3, issue.12, pp.1416-1445, 2013. ,
Functional genomic landscape of acute myeloid leukaemia, Nature. oct, vol.562, issue.7728, pp.526-557, 2018. ,
Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia, Blood Cancer J. 13 mars, vol.5, issue.3, p.292, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01218497
Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing, Leukemia. avr, vol.30, issue.4, pp.966-70, 2016. ,
Fast and accurate long-read alignment with Burrows-Wheeler transform, Bioinforma Oxf Engl. 1 mars, vol.26, issue.5, pp.589-95, 2010. ,
A framework for variation discovery and genotyping using next-generation DNA sequencing data, Nat Genet. mai, vol.43, issue.5, pp.491-499, 2011. ,
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing, Genome Res. 1 mars, vol.22, issue.3, pp.568-76, 2012. ,
An ensemble approach to accurately detect somatic mutations using SomaticSeq, Genome Biol. 17 sept, vol.16, p.197, 2015. ,
ANNOVAR: functional annotation of genetic variants from highthroughput sequencing data, Nucleic Acids Res. sept, vol.38, issue.16, p.164, 2010. ,
Integrative genomics viewer, Nat Biotechnol. janv, vol.29, issue.1, pp.24-30, 2011. ,
Integrative Genomics Viewer (IGV): highperformance genomics data visualization and exploration, Brief Bioinform. mars, vol.14, issue.2, pp.178-92, 2013. ,
From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards, Genome Med, vol.15, issue.1, p.18, 2018. ,
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma, Mol Cancer Ther. juin, vol.12, issue.6, pp.901-913, 2013. ,
Abstract CT152: Phase I dose-and regimen-finding study of NVP-HDM201 in pts with advanced TP53 wt acute leukemias, Cancer Res. 1 juill, vol.77, pp.152-152, 2013. ,
BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction, Cell Rep. 16 janv, vol.6, issue.1, pp.81-92, 2014. ,
Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities, Cancer Cell. mars, vol.27, issue.3, pp.382-96, 2015. ,
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors, Cancer Discov. févr, vol.5, issue.2, pp.118-141, 2015. ,
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets, Nat Rev Cancer, vol.12, issue.8, pp.572-580, 2012. ,
Prioritizing targets for precision cancer medicine, Ann Oncol. 1 déc, vol.25, issue.12, pp.2295-303, 2014. ,
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Ann Oncol. 1 sept, vol.29, issue.9, pp.1895-902, 2018. ,
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients, Blood, vol.124, issue.17, pp.2705-2717, 2014. ,
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies, Proc Natl Acad Sci, vol.114, issue.36, pp.7554-63, 2017. ,
Clinical Results of Hypomethylating Agents in AML Treatment, J Clin Med. 25 déc, vol.4, issue.1, pp.1-17, 2014. ,
Targeting the bone marrow microenvironment in acute leukemia, Leuk Lymphoma. 12 févr, pp.1-11, 2018. ,
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies, 2015. ,
, Disponible sur
Improved statistical methods for hit selection in highthroughput screening, J Biomol Screen. déc, vol.8, issue.6, pp.634-681, 2003. ,
Data Analysis Approaches in High Throughput Screening, El-Shemy H, éditeur. Drug Discovery, 2013. ,
Statistical practice in high-throughput screening data analysis, Nat Biotechnol. févr, vol.24, issue.2, pp.167-75, 2006. ,
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias, Leukemia. juill, vol.25, issue.7, pp.1147-52, 2011. ,
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia, Leukemia. mai, vol.26, issue.5, pp.1106-1113, 2012. ,
Mutated and nonmutated TP53 as targets in the treatment of leukaemia, Br J Haematol. mai, vol.141, issue.4, pp.445-53, 2008. ,
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes, N Engl J Med, vol.24, issue.21, pp.2023-2059, 2016. ,
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions, Blood. 1 mai, vol.103, issue.9, pp.3278-81, 2004. ,
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature. 16 juill, vol.523, issue.7560, pp.352-358, 2015. ,
IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo, Nature. 29 janv, vol.517, issue.7536, pp.626-656, 2015. ,
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins, Nat Med, vol.22, issue.6, pp.672-680, 2016. ,
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a nonrandomised, open-label phase 2 study, Lancet Oncol. mars, vol.14, issue.3, pp.249-56, 2013. ,
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.26, issue.13, pp.2139-2185, 2008. ,
Characteristics of lung cancers harboring NRAS mutations, Clin Cancer Res Off J Am Assoc Cancer Res. 1 mai, vol.19, issue.9, pp.2584-91, 2013. ,
Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma, Br J Haematol, vol.159, issue.4, pp.430-470, 2012. ,
First-inhuman, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.18, issue.17, pp.4806-4825, 2012. ,
Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2, J Med Chem. 14 févr, vol.62, issue.3, pp.1125-1162, 2019. ,
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase, Blood. 1 févr, vol.109, issue.3, pp.862-869, 2007. ,
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs, Cell Rep. 29 sept, vol.12, issue.12, pp.1978-85, 2015. ,
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial, Lancet Oncol. déc, vol.13, issue.12, pp.1218-1242, 2012. ,
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors, Mol Cancer Ther. mai, vol.7, issue.5, pp.1237-1282, 2008. ,
, Landscape of Pharmacogenomic Interactions in Cancer. Cell. 28 juill, vol.166, issue.3, pp.740-54, 2016.
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies, Biomark Res, vol.7, issue.2018 ,
Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes, Cancer Res. 15 sept, vol.78, issue.18, pp.5363-74, 2018. ,
SF3B1 mutations constitute a novel therapeutic target in breast cancer, J Pathol. mars, vol.235, issue.4, pp.571-80, 2015. ,
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis, Leukemia, vol.30, issue.8, pp.1701-1708, 2016. ,
Midostaurin approved for FLT3-mutated AML, Blood, vol.29, issue.26, pp.3403-3409, 2017. ,
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors, J Clin Oncol Off J Am Soc Clin Oncol. 20 janv, vol.35, issue.3, pp.352-60, 2017. ,
Small molecule activation of NOTCH signaling inhibits acute myeloid leukemia, Sci Rep, vol.23, p.26510, 2016. ,
Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition, Mol Cancer Ther. mars, vol.13, issue.3, pp.724-756, 2014. ,
A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice, Cancer Res. 1 juin, vol.72, issue.11, pp.2822-2854, 2012. ,
CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN, J Biol Chem. 5 juill, vol.288, issue.27, pp.19459-70, 2013. ,
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms, Cancer Cell. 11 mai, vol.27, issue.5, pp.658-70, 2015. ,
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors, Clin Cancer Res Off J Am Assoc Cancer Res. 15 avr, vol.17, issue.8, pp.2502-2513, 2011. ,
Efficacy and safety of vismodegib in advanced basal-cell carcinoma, N Engl J Med. 7 juin, vol.366, issue.23, pp.2171-2180, 2012. ,
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, N Engl J Med, vol.373, issue.18, pp.1697-708, 2015. ,
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscleinvasive Bladder Cancer, Eur Urol. déc, vol.68, issue.6, pp.959-67, 2015. ,
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide, Mol Cancer Ther, vol.12, issue.11, pp.2529-2569, 2013. ,
, JAK inhibitor in CALR-mutant myelofibrosis. -PubMed -NCBI
,
Inactivating CUX1 mutations promote tumorigenesis, Nat Genet. janv, vol.46, issue.1, pp.33-41, 2014. ,
CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers, Nat Rev Cancer, vol.14, issue.10, pp.673-82, 2014. ,
MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia, N Engl J Med. 6 août, vol.373, issue.6, pp.584-590, 2015. ,
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy, BMC Cancer, vol.23, issue.1, p.211, 2017. ,
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors, J Clin Oncol Off J Am Soc Clin Oncol. 10 déc, vol.29, issue.35, pp.4688-95, 2011. ,
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08), Eur Urol. juill, vol.64, issue.1, pp.150-158, 2013. ,
, PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
,
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer, Oncogene. 3 mars, vol.35, issue.9, pp.1163-1172, 2016. ,
Oncogenic RIT1 mutations in lung adenocarcinoma, Oncogene. 28 août, vol.33, issue.35, pp.4418-4441, 2014. ,